The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Interim analysis of the LOTIS-3 trial
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, provides an overview of the interim analysis of the open-label, Phase II LOTIS-3 trial (NCT03684694) investigating loncastuximab tesirine plus ibrutinib in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Out of the 35 patients were enrolled, 13 and 22 patients were diagnosed with the germinal center B-cell like (GCB) subtype, and non-GCB DLBCL respectively. Loncastuximab tesirine demonstrated promising activity and had an acceptable safety profile, with the complete response rate (CRR) being 34.3% in the overall DLBCL cohort. However, duration of response was not reached in the cohort.. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
